Gene therapy for Wiskott-Aldrich syndrome

Current Gene Therapy

Volumn 14, Issue 6, 2014, Pages 413-421

  Bosticardo, Marita ^a   Ferrua, Francesca ^a,b   Cavazzana, Marina ^c,d   Aiuti, Alessandro ^a,b,e  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d University of Sorbonne Paris la Cité   (France)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Gene therapy; Lentiviral vector; Primary immunodeficiency; Wiskott Aldrich syndrome

Indexed keywords

MURINAE;

WISKOTT ALDRICH SYNDROME PROTEIN;

ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MOUSE; THERAPEUTIC USE; WISKOTT-ALDRICH SYNDROME;

ANIMALS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN FAMILY;

EID: 84924762364     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140918103731     Document Type: Article

References (68)

1. [1] Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2006; 117(4): 725-38.
2. [2] Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103(2): 456-64.
3. [3] Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 1995; 9(4): 414-7.
4. [4] Notarangelo LD, Mazza C, Giliani S, et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 2002; 99(6): 2268-9.
5. [5] Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115(16): 3231-8.
6. [6] Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001; 27(3): 313-7.
7. [7] Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006; 108(7): 2182-9.
8. [8] Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009; 113(25): 6288-95.
9. [9] Catucci M, Castiello MC, Pala F, Bosticardo M, Villa A. Autoimmunity in wiskott-Aldrich syndrome: an unsolved enigma. Front Immunol 2012; 3: 209.
10. [10] Ochs HD. The Wiskott-Aldrich syndrome. Isr Med Assoc J 2002; 4(5): 379-84.
11. [11] Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125(6 Pt 1): 876-85.
12. [12] Schurman SH, Candotti F. Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol 2003; 15(4): 446-53.
13. [13] Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 2002; 99(8): 2694-702.
14. [14] Pai S-Y, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006; 38(10): 671-9.
15. [15] Cohen JM, Sebire NJ, Harvey J, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reducedintensity allogeneic stem-cell transplantation. Blood 2007; 110(6): 2209-14.
16. [16] Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/Xlinked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 1997; 90(7): 2680-9.
17. [17] Imai K, Nonoyama S, Ochs HD. WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype. Curr Opin Allergy Clin Immunol 2003; 3(6): 427-36.
18. [18] Mahlaoui N, Pellier I, Mignot C, et al. Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. Blood 2013; 121(9): 1510-6.
19. [19] Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009; 15(1 Suppl): 84-90.
20. [20] Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, doubleblind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011; 118(1): 28-36.
21. [21] Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011; 118(6): 1675-84.
22. [22] Shin CR, Kim M-O, Li D, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant 2012; 47(11): 1428-35.
23. [23] Filipovich AH, Stone J V, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001; 97(6): 1598-603.
24. [24] Kobayashi R, Ariga T, Nonoyama S, et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 2006; 135(3): 362-6.
25. [25] Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008; 111(1): 439-45.
26. [26] Eapen M, Ahn KW, Orchard PJ, et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transplant 2012; 18(9): 1438-45.
27. [27] Stepensky P, Krauss A, Goldstein G, et al. Impact of conditioning on outcome of hematopoietic stem cell transplantation for wiskott-Aldrich syndrome. J Pediatr Hematol Oncol 2013; 35(6): e234-8.
28. [28] Candotti F, Facchetti F, Blanzuoli L, Stewart DM, Nelson DL, Blaese RM. Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying “null” mutations. Gene Ther 1999; 6(6): 1170-4.
29. [29] Huang MM, Tsuboi S, Wong A, et al. Expression of human Wiskott-Aldrich syndrome protein in patients’ cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins. Gene Ther 2000; 7(4): 314-20.
30. [30] Wada T, Jagadeesh GJ, Nelson DL, Candotti F. Retrovirusmediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. Hum Gene Ther 2002; 13(9): 1039-46.
31. [31] Strom TS, Gabbard W, Kelly PF, Cunningham JM, Nienhuis AW. Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein. Gene Ther 2003; 10(9): 803-9.
32. [32] Dupré L, Trifari S, Follenzi A, et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther J Am Soc Gene Ther 2004; 10(5): 903-15.
33. [33] Jones GE, Zicha D, Dunn GA, Blundell M, Thrasher A. Restoration of podosomes and chemotaxis in Wiskott-Aldrich syndrome macrophages following induced expression of WASp. Int J Biochem Cell Biol 2002; 34(7): 806-15.
34. [34] Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 1998; 9(1): 81-91.
35. [35] Zhang J, Shehabeldin A, da Cruz LA, et al. Antigen receptorinduced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med 1999; 190(9): 1329-42.
36. [36] Klein C, Nguyen D, Liu C, et al. Gene therapy for Wiskott-Aldrich syndrome : rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 2003; 101(6): 2159-66.
37. [37] Strom TS, Turner SJ, Andreansky S, et al. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. Blood 2003; 102(9): 3108-16.
38. [38] Dewey RA, Avedillo Díez I, Ballmaier M, et al. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro. Exp Hematol 2006; 34(9): 1161-9.
39. [39] Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363(20): 1918-27.
40. [40] Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of Xlinked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12(4): 401-9.
41. [41] Hacein-Bey-Abina S, Von KC, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302(5644): 415-9.
42. [42] Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118(9): 3143-50.
43. [43] Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24(6): 687-96.
44. [44] Galy A, Roncarolo M-G, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther 2008; 8(2): 181-90.
45. [45] Martín F, Toscano MG, Blundell M, et al. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther 2005; 12(8): 715-23.
46. [46] Charrier S, Dupré L, Scaramuzza S, et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 2007; 14(5): 415-28.
47. [47] Dupré L, Marangoni F, Scaramuzza S, et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther 2006; 17(3): 303-13.
48. [48] Blundell MP, Bouma G, Calle Y, Jones GE, Kinnon C, Thrasher AJ. Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy. Mol Ther J Am Soc Gene Ther 2008; 16(5): 836-44.
49. [49] Marangoni F, Bosticardo M, Charrier S, et al. Evidence for longterm efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther J Am Soc Gene Ther 2009; 17(6): 1073-82.
50. [50] Bosticardo M, Draghici E, Schena F, et al. Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2011; 127(6): 1376-845.
51. [51] Catucci M, Prete F, Bosticardo M, et al. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome. Gene Ther 2012; 19(12): 1150-8.
52. [52] Mantovani J, Charrier S, Eckenberg R, et al. Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome. J Gene Med 2009; 11(8): 645-54.
53. [53] Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther J Am Soc Gene Ther 2009; 17(11): 1919-28.
54. [54] Scaramuzza S, Biasco L, Ripamonti A, et al. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol Ther 2013; 21(1): 175-84.
55. [55] Avedillo Díez I, Zychlinski D, Coci EG, et al. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm 2011; 8(5): 1525-37.
56. [56] Astrakhan A, Sather BD, Ryu BY, et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood 2012; 119(19): 4395-407.
57. [57] Koldej RM, Carney G, Wielgosz MM, et al. Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors. Hum Gene Ther Clin Dev 2013; 24(2): 77-85.
58. [58] Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360(5): 447-58.
59. [59] Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363(4): 355-64.
60. [60] Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011; 3(97): 97-80.
61. [61] Deichmann A, Brugman MH, Bartholomae CC, et al. Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther 2011; 19(11): 2031-9.
62. [62] Wang GP, Berry CC, Malani N, et al. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 2010; 115(22): 4356-66.
63. [63] Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med 2014; 6(227): 227-33.
64. [64] Witzel MGW, Braun CJ, Boztug K, Klein C. Gene therapy for Wiskott-Aldrich syndrome. Expert Opin Orphan Drugs 2013; 1: 705-15.
65. [65] Corrigan-Curay J, Cohen-Haguenauer O, O’Reilly M, et al. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther 2012; 20(6): 1084-94.
66. [66] Seymour LW, Thrasher AJ. Gene therapy matures in the clinic. Nat Biotechnol 2012; 30(7): 588-93.
67. [67] Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011; 3(97): 97-79.
68. [68] Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013; 341(6148): 1233151.